1. Древаль А.В., Марченкова Л.А., Крюкова И.В. Частота переломов бедра и предплечья и затраты на их лечение в Московской области. Остеопороз и остеопатии, 2005; 2: 8–13.
2. Евстигнеева Л.П., Лесняк О.М., Пивень А.И. Эпидемиология остеопоротических переломов позвоночника по данным рентгеноморфометрического анализа среди популяционной выборки жителей г. Екатеринбурга 50 лет и старше. Остеопороз и остеопатии. 2001; 2: 2–6.
3. Ершова О.Б., Семенова О.В., Дегтярев А.А. Результаты проспективного изучения исходов переломов проксимального отдела бедра. Остеопороз и остеопатии. 2000; 1: 9–10.
4. Лесняк Ю.Ф. Анализ затрат при профилактике перелома проксимального отдела бедра, ассоциированного с остеопорозом. Остеопороз и остеопатии. 2003; 3: 2–5.
5. Марченкова Л.А., Древаль А.В., Крюкова И.В. и др. Эффективность Бивалоса (стронция ранелата) у больных постменопаузальным остеопорозом, не принимающих добавки кальция и витамина D. Проблемы эндокринологии. 2010; 1: 35–41.
6. Меньшикова Л.В., Храмцова Н.А., Ершова О.Б. и др. Ближайшие и отдаленные исходы переломов проксимального отдела бедра у лиц пожилого возраста и их медико-социальные последствия (по данным многоцентрового исследования). Остеопороз и остеопатии. 2002; 1: 8–11.
7. Михайлов Е.Е., Беневоленская Л.И., Мылов Н.М. Распространенность переломов позвоночника в популяционной выборке лиц 50 лет и старше. Вестник травматологии и ортопедии им Н.Н.Приорова. 1997; 3: 20–7.
8. Михайлов Е.Е., Беневоленская Л.И., Аникин С.Г. и др. Частота переломов проксимального отдела бедренной кости и дистального отдела предплечья среди городского населения России. Остеопороз и остеопатии. 1999; 3: 2–6.
9. Рожинская Л.Я., Беневоленская Л.И., Родионова С.С. Бивалос: клиническая эффективность в Российской медицинской практике. Остеопороз и остеопатии. 2007; 3.
10. Bickerstaff DR, Kanis JA. Algodystrophy: an under-recognised complication of minor trauma. British J Rheumatol 1994; 33: 240–8.
11. Cooper С et al. A population based study of survival after osteoporotic fractures. American Journal of Epidemiology 1993; 137: 1001–5.
12. Cooper C. Long-term protection with strontium ranelate. Osteoporosis int 2008; 19 (Suppl 1): S213.
13. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002; 359: 1761–7.
14. Finnern HW, Sykes DP. The hospital cost of a vertebral fracture in the EU: estimates using national data sets. Osteoporosis International 2003; 14: 429–36.
15. Gibson MJ. The prevention of falls in later life. Danish Medical Bulletin 1987; 34 (Suppl. 4): 1–24.
16. Gullberg B, Johnell O. Kanis JA. World-wide projections for hip fracture. Osteoporosis International 1997; 7: 407–13.
17. Johnell О, Kanis JA. An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporosis International 2004; 15: 897–902.
18. Johnell О et al. The burden of hospitalised fractures in Sweden. Osteoporosis International 2005; 16: 222–8.
19. Kado DM et al. Vertebral fractures and mortality in older women. Archives of Internal Medicine 1999; 159: 1215–20.
20. Kanis JA, Burlet N, Cooper C et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008;19: 399–428.
21. Kanis JA, Pitt FA. Epidemiology of osteoporosis. Bone 1992; 13: S7–S15.
22. Kanis JA et al. Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technology Assessment 2002; 6: 1–146.
23. Kanis JA et al. The components of excess mortality after hip fracture. Bone 2003; 32: 468–73.
24. Kanis JA et al. Excess mortality after hospitalisation for vertebral fracture. Osteoporosis International 2004; 15: 108–12.
25. Kanis JA et al. Risk and burden of vertebral fractures in Sweden. Osteoporosis International 2004; 15: 20–6.
26. Kanis JA, Johnell O. On behalf of the Committee of Scientific Advisors of the International Osteoporosis Foundation. Requirements for DXA for the management of osteoporosis in Europe. Osteoporosis International 2005; 16: 229–38.
27. Kaukonen JP et al. Functional recovery after fractures of the distal forearm: analysis of radiographic and other factors affecting the outcome. Annals Chirurgiae et Gynaecologiae 1988; 77: 27–31.
28. Lindsay R, Burge RT, Strauss DM. One year outcomes and costs following a vertebral fracture. Osteoporosis International 2005; 16: 78–85.
29. Marques P, Roux C, de la Loge C. et al. Strontium ranelate prevents quality of life impairment in post-menopausal women with established vertebral osteoporosis. Osteoporosis Int 2008; 19 (4): 503–10.
30. Marottoli RA, Berkman LF, Cooney LM. Decline in physical function following hip fracture. J Am Gerontol Soc 1992; 40: 861–6.
31. Melton LJ III. Epidemiology of fractures. In: Riggs BL, Melton LJ, UI eds. Osteoporosis: etiology, diagnosis, and management. 2nd ed. Philadelphia, Lippincott-Raven 1995.
32. Melton LJ III. Adverse outcomes of osteoporotic fractures in the general population. J Bone and Mineral Research 2003; 18: 1139–41.
33. Meunier PJ, Roux C, Seeman E et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. New Eng J Med 2004; 350: 459–68.
34. National Osteoporosis Foundation. Osteoporosis: cost-effectiveness analysis and review of the evidence for prevention, diagnosis and treatment. Osteoporosis International 1998; 8 ( Suppl 4): S1–S88.
35. Nevitt MC et al. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Annals of Internal Medicine 1998; 128: 793–800.
36. Norton R et al. Declines in physical functioning attributable to hip fracture among older people: a follow-up study of case-control participants. Disability Rehabilitation 2000; 22: 345–51.
37. Oleksik A et al. Health-related quality of life (HRQOL) in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone and Mineral Research 2000; 15: 1384–92.
38. O'Neill TW et al. The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone and Mineral Research 1996; 11: 1010–18.
39. Polder JJ et al. Costs of disease in the Netherlands 1994. Rotterdam, Erasmus Universiteit, Instituut Maatschappelijke Gezondheidszorg. Instituut voor Medische Technology Assessment 1997; 1: 295.
40. Poor G et al. Determinants of reduced survival following hip fractures in men. Clinical Orthopaedics and Related Research 1995; 319: 260–5.
41. Reginster JY, Meuniier PJ, Roux J et al. Strontium ranelate: an anti-osteoporotic treatment demonstrated vertebral and nonvertebral anti fracture efficacy over 5 years in post menopausal osteoporotic women. Osteoporosis Int 2006; 17 (Suppl 1): s11–s12.
42. Reginster JY, Seeman E, De Vernejoul MC et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis treatment of peripheral osteoporosis (TROPOS) study. Clin Endocrinol Metab 2005; 90: 2816–22.
43. WHO Scientific Group on the Burden of Musculoskeletal Conditions at the Start of the New Millennium. The burden of musculoskeletal conditions at the start of the new millennium. Geneva.  World Health Organization 2003. WHO Technical Report Series; 919.

И.В.Крюкова, Л.А.Марченкова, А.В.Древаль 

ГУ Московский областной научно-исследовательский клинический институт им. М.Ф.Владимирского